KMT2A and myeloid leukemia: By contrast, menin acts as an oncogenic cofactor of MLL (mixed lineage leukemia) fusion protein in aggressive lymphoid and myeloid leukemias, and the interruption of menin−MLL interaction can block the oncogenic function of the MLL fusion protein [15].